Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective
- 7 November 2008
- journal article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 10 (4), 537-51
- https://doi.org/10.1208/s12248-008-9056-1
Abstract
The opioids are commonly used to treat acute and severe pain. Long-term opioid administration eventually reaches a dose ceiling that is attributable to the rapid onset of analgesic tolerance coupled with the slow development of tolerance to the untoward side effects of respiratory depression, nausea and decreased gastrointestinal motility. The need for effective-long term analgesia remains. In order to develop new therapeutics and novel strategies for use of current analgesics, the processes that mediate tolerance must be understood. This review highlights potential pharmacokinetic (changes in metabolite production, metabolizing enzyme expression, and transporter function) and pharmacodynamic (receptor type, location and functionality; alterations in signaling pathways and cross-tolerance) aspects of opioid tolerance development, and presents several pharmacodynamic modeling strategies that have been used to characterize time-dependent attenuation of opioid analgesia.Keywords
This publication has 116 references indexed in Scilit:
- Oxycodone induces overexpression of P‐glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley ratsJournal of Pharmaceutical Sciences, 2007
- Region‐dependent attenuation of μ opioid receptor‐mediated G‐protein activation in mouse CNS as a function of morphine toleranceBritish Journal of Pharmacology, 2007
- Targeting opioid receptor heterodimers: Strategies for screening and drug developmentThe AAPS Journal, 2006
- Tissue Distribution of Opioid Receptor Gene Expression in the RatBiochemical and Biophysical Research Communications, 1996
- Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skinNeuroscience Letters, 1995
- Opioid rotation for toxicity reduction in terminal cancer patientsJournal of Pain and Symptom Management, 1995
- The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complexLife Sciences, 1994
- κ‐Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the ratBritish Journal of Pharmacology, 1988
- High-Dose Morphine and Methadone in Cancer PatientsClinical Pharmacokinetics, 1986
- The Relationship of Pharmacokinetics to Pharmacological ActivityClinical Pharmacokinetics, 1976